These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26237499)

  • 1. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
    Sereno M; Moreno V; Moreno Rubio J; Gómez-Raposo C; García Sánchez S; Hernández Jusdado R; Falagan S; Zambrana Tébar F; Casado Sáenz E
    Anticancer Drugs; 2015 Oct; 26(9):1004-7. PubMed ID: 26237499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
    Imielinski M; Greulich H; Kaplan B; Araujo L; Amann J; Horn L; Schiller J; Villalona-Calero MA; Meyerson M; Carbone DP
    J Clin Invest; 2014 Apr; 124(4):1582-6. PubMed ID: 24569458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
    Casadei Gardini A; Chiadini E; Faloppi L; Marisi G; Delmonte A; Scartozzi M; Loretelli C; Lucchesi A; Oboldi D; Dubini A; Frassineti GL; Ulivi P
    BMC Cancer; 2016 Jul; 16():429. PubMed ID: 27388325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
    Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive thyroid cancer: targeted therapy with sorafenib.
    Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
    Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
    Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
    Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
    Abdel-Rahman O
    Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
    BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: targeting multiple tyrosine kinases in cancer.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare primary liver tumor that responded to sorafenib.
    Seino S; Tsuchiya A; Watanabe M
    Gastroenterology; 2014 Dec; 147(6):1226-7. PubMed ID: 25450081
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutations in chronic lymphocytic leukemia.
    Jebaraj BM; Kienle D; Bühler A; Winkler D; Döhner H; Stilgenbauer S; Zenz T
    Leuk Lymphoma; 2013 Jun; 54(6):1177-82. PubMed ID: 23088640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
    Lee DW; Chang H; Kim YJ; Kim KM; Lee HJ; Lee JS
    J Clin Oncol; 2014 Apr; 32(11):e42-5. PubMed ID: 24449236
    [No Abstract]   [Full Text] [Related]  

  • 20. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.
    Goldman JM; Gray JE
    Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.